I am not mentioning negatively or complaining about the fact they are looking at the "market potential" at all, rather just the time frames they use for two of their potential product lines.
They say: "A summary of global market sizes according to the potential application for RECCE 327 is as follows:
Antibiotics - around US$40b, estimated to climb 12.5% to US$45b by 2019
Anti-cancer - around US$100b, estimated to climb 50% to US$150b by 2018
Anti-viral - around US$30b, estimated to climb 333% to US$100b by 2025"
Surely even the most bullish cannot be even remotely expecting anything to market by 2018 or 2019?
Yet they are trying to promote or imply the RECCE327 will be available to take advantage of the above time frames.
Do you honestly believe that is remotely likely?
Cheers
Cabe
RCE Price at posting:
29.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)